Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
COLL Collegium Pharmaceutical Inc
- Stocks
- Healthcare
- NASDAQ: COLL
Price (delayed)
$29.57
Market cap
$950.44M
P/E Ratio
21.74
Dividend/share
N/A
EPS
$1.36
Enterprise value
$1.68B
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
Highlights
The revenue is up by 17% year-on-year and by 5% since the previous quarter
Collegium Pharmaceutical's gross profit has increased by 13% YoY
The quick ratio has declined by 17% year-on-year but it rose by 12% since the previous quarter
The net income has plunged by 53% YoY and by 37% from the previous quarter
Collegium Pharmaceutical's EPS has plunged by 52% YoY and by 36% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Key stats
What are the main financial stats of COLL
Market
Valuations
Earnings
Shares outstanding
32.14M
Market cap
$950.44M
Enterprise value
$1.68B
Price to earnings (P/E)
21.74
Price to book (P/B)
3.97
Price to sales (P/S)
1.42
EV/EBIT
11.77
EV/EBITDA
5.38
EV/Sales
2.53
Revenue
$664.28M
Gross profit
$383.21M
Operating income
$138.41M
Net income
$43.89M
EBIT
$142.49M
EBITDA
$311.83M
Free cash flow
$196.56M
Per share
Balance sheet
Liquidity
EPS
$1.36
EPS diluted
$1.21
Free cash flow per share
$6.18
Book value per share
$7.45
Revenue per share
$20.89
TBVPS
$20.28
Total assets
$1.63B
Total liabilities
$1.4B
Debt
$844.21M
Equity
$234.43M
Working capital
$40.84M
Debt to equity
3.6
Current ratio
1.08
Quick ratio
0.92
Net debt/EBITDA
2.33
Margins
Efficiency
Dividend
EBITDA margin
46.9%
Gross margin
57.7%
Net margin
6.6%
Operating margin
20.8%
Return on assets
2.9%
Return on equity
19.2%
Return on invested capital
18.2%
Return on capital employed
12.4%
Return on sales
21.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COLL stock price
How has the Collegium Pharmaceutical stock price performed over time
Intraday
-1.2%
1 week
-1.04%
1 month
1.48%
1 year
-8.17%
YTD
3.21%
QTD
-0.94%
Financial performance
How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$664.28M
Gross profit
$383.21M
Operating income
$138.41M
Net income
$43.89M
Gross margin
57.7%
Net margin
6.6%
COLL's net margin has dropped by 60% year-on-year and by 40% since the previous quarter
The net income has plunged by 53% YoY and by 37% from the previous quarter
Collegium Pharmaceutical's operating margin has decreased by 38% YoY and by 21% QoQ
Collegium Pharmaceutical's operating income has decreased by 28% YoY and by 17% QoQ
Price vs fundamentals
How does COLL's price correlate with its fundamentals
Growth
What is Collegium Pharmaceutical's growth rate over time
Valuation
What is Collegium Pharmaceutical stock price valuation
P/E
21.74
P/B
3.97
P/S
1.42
EV/EBIT
11.77
EV/EBITDA
5.38
EV/Sales
2.53
Collegium Pharmaceutical's EPS has plunged by 52% YoY and by 36% from the previous quarter
COLL's P/E is 44% above its last 4 quarters average of 15.1
The price to book (P/B) is 14% lower than the last 4 quarters average of 4.6
The equity is up by 6% year-on-year and by 2.4% since the previous quarter
COLL's price to sales (P/S) is 25% lower than its 5-year quarterly average of 1.9 and 16% lower than its last 4 quarters average of 1.7
The revenue is up by 17% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Collegium Pharmaceutical business performance
The company's return on assets has shrunk by 64% YoY and by 43% QoQ
The ROE has shrunk by 59% YoY and by 37% QoQ
The ROIC has contracted by 49% YoY and by 26% from the previous quarter
Collegium Pharmaceutical's ROS has decreased by 42% YoY and by 21% from the previous quarter
Dividends
What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COLL.
Financial health
How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 17% more than its total liabilities
Collegium Pharmaceutical's total liabilities has surged by 57% YoY but it has decreased by 2.6% QoQ
Collegium Pharmaceutical's total assets has increased by 46% YoY
COLL's debt is up by 34% year-on-year
The debt to equity rose by 27% YoY but it fell by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.